Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

被引：0

作者：

Fournier, D. ^{[1
]}

Jouneau, S. ^{[2
]}

Bouzille, G. ^{[3
]}

Polard, E. ^{[4
]}

Osmont, M. N. ^{[1
]}

Scailteux, L. M. ^{[4
]}

机构：

[1] Rennes Univ Hosp, Pharmacovigilance Pharmacoepidemiol & Drug Infor, Rennes, France

[2] Univ Rennes, CHU Rennes, INSERM, EHESP,Dept Resp Med,Competence Ctr Rare Pulm Dis, Rennes, France

[3] Univ Rennes, CHU Rennes, INSERM, LTSI UMR 1099, Rennes, France

[4] Univ Rennes, Rennes Univ Hosp, Pharmacovigilance Pharmacoepidemiol & Drug Inform, Reperes Pharmacoepidemiol & Hlth Serv Res EA 7449, Rennes, France

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2022年 / 36卷

关键词：

adverse drug reaction; idiopathic pulmonary fibrosis; nintedanib; pirfenidone; safety profile;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PM2-014

引用

页码：77 / 78

页数：2